ARE YOU WARY of the ‘use-it-or-lose-it’ nature of pure term insurance plans? Intrigued by an insurance plan that promises to refund every premium you’ve ever paid? Enter the zero-cost term insurance plan.
Since it was launched in 2022, many companies have brought out their offerings to tap into customer demand. Companies like Max Life Insurance, HDFC Life Insurance, Bajaj Allianz Life, Canara HSBC Life Insurance, and ICICI Prudential Life provide these ‘zero-cost’ term plans, allowing policyholders to close the policy and receive a full premium refund or continue until maturity without any cashback benefits.
For the uninitiated, there are three fundamental forms of term insurance plans: The regular term plan, where the policyholder receives coverage for a fixed duration; the term plan with return of premium or TROP plan, which gives policyholders the option to get back premiums in case they survive the policy term; and, finally, the zero-cost term plan, which is a hybrid of the other two and gives policyholders the option of reclaiming premiums during the term.
Though this last option seems enticing, investors must read the fine print carefully. Besides, once you choose one type of policy, you cannot switch to another.
THE DISTINCTIONS
Before you proceed, there are a few more differences you need to keep in mind. In the regular plan, if the policyholder passes away during the term, the nominee is entitled to a death benefit, either as a lump sum or as periodic payments. Since it’s purely coverage for risk, there’s no maturity benefit if the policyholder outlives the term. These plans are budget-friendly, offering substantial coverage against life’s uncertainties.
هذه القصة مأخوذة من طبعة February 04, 2024 من Business Today India.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة February 04, 2024 من Business Today India.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 8500 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
BANDHAN AT A CROSSROADS
THE BELEAGUERED LENDER, LED BY CHANDRA SHEKHAR GHOSH, HAS FACED A HOST OF CHALLENGES IN RECENT TIMES. IT HAS READIED A BLUEPRINT TO DEAL WITH THEM. BUT WILL IT SUCCEED WITHOUT GHOSH AT THE HELM?
RESULT AND REPERCUSSIONS
After the verdict, the Street has turned cautious with analysts expecting the new government to reassess some of its policy priorities
CONTINUITY WITH CHANGE
The economy seems to be well placed. The election results could mean a slower pace of reforms, but the focus on development is likely to continue
D-STREET ANGELS
FACED WITH A DEARTH OF PURE-PLAY THEMES IN THE SECONDARY MARKETS, SEASONED INVESTORS LIKE VIJAY KEDIA, MUKUL MAHAVIR AGRAWAL, AND THE JHUNJHUNWALAS HAVE TRAINED THEIR SIGHTS ON THE START-UP WORLD BY RAHUL OBEROI
What The Future Holds For Amazon India
The E-commerce Giant Has Seen Steady Growth Since Its Entry Into India In 2013, But The Offline Piece Remains A Challenge. After Losing Out On The Future Retail Acquisition, How Does It Plan To Keep The Growth Engines Revving?
Time To Unshackle?
Young India Is Obsessed With Apps. But The Gateway To Them Is Closely Guarded By Two Tech Behemoths-google And Apple-who Control 99% Of The Market In India. Is It Time For India To Break Free From This Duopoly And Have Its Own App Store?
"Understand what drives key talent"
Novartis India is a part of the Basel, Switzerland-headquartered pharma major Novartis AG
MILLENNIALS MISSING HOME
SKY-HIGH PROPERTY PRICES, COUPLED WITH SLOW INCOME GROWTH, HAVE MADE THE DREAM OF OWNING A HOME A DISTANT ONE FOR MANY MILLENNIALS. THIS COULD LEAD TO STAGNATION IN SOCIAL MOBILITY AND POTENTIALLY DEEPEN EXISTING SOCIAL INEQUALITIES
SIGNATURE MOVE
SIGNATURE GLOBAL, A LEADER IN AFFORDABLE HOUSING, IS LOOKING TO GET BACK IN THE BLACK WITH A SHIFT IN FOCUS TO MID-SEGMENT AND PREMIUM HOUSING AFTER LOW-COST PROJECTS BECAME UNVIABLE FOR DEVELOPERS
MAKING A MARK
PHARMA MAJOR GLENMARK IS STRATEGICALLY PLOTTING ITS WAY UP, ALL BY SHIFTING ITS FOCUS TO BRANDED AND SPECIALITY MEDICINE AND ENSURING IT GETS ITS R&D RIGHT